share_log

Seelos Therapeutics | EFFECT: Others

SEC announcement ·  Mar 18 18:09
Summary by Futu AI
Seelos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Notice of Effectiveness issued by the United States Securities and Exchange Commission (SEC) on March 15, 2024, at 4:00 P.M. The notice pertains to the Form S-1 filing, under the file number 333-276831. This development marks a key step for Seelos Therapeutics in its regulatory compliance and reporting process, allowing the company to move forward with its planned activities as outlined in the Form S-1 registration.
Seelos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Notice of Effectiveness issued by the United States Securities and Exchange Commission (SEC) on March 15, 2024, at 4:00 P.M. The notice pertains to the Form S-1 filing, under the file number 333-276831. This development marks a key step for Seelos Therapeutics in its regulatory compliance and reporting process, allowing the company to move forward with its planned activities as outlined in the Form S-1 registration.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.